Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 9, 2026, 5:08 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 2,262 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Melanoma Syndrome Clear all
Completed Phase 1 Interventional

Sodium Stibogluconate With Interferon Alpha-2b for Patients With Advanced Malignancies

NCT00629200
View directory record Official record
Conditions
Advanced Cancer, Solid Tumors
Interventions
Sodium Stibogluconate, Interferon Alpha-2b
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
2
States / cities
Albuquerque, New Mexico • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 15, 2018 · Synced Oct 9, 2026, 5:08 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Modifying Young Adult Skin Cancer Risk and Protective Behaviors

NCT03313492
View directory record Official record
Conditions
Melanoma and Other Malignant Neoplasms of Skin
Interventions
UV4.me2, UV4.me, E-Pamphlet
Behavioral
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years to 25 Years
Enrollment
1,746 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
2
States / cities
New Brunswick, New Jersey • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 30, 2022 · Synced Oct 9, 2026, 5:08 AM EDT
Terminated Phase 1 Interventional

A Multicenter Phase I Study of MRX34, MicroRNA miR-RX34 Liposomal Injection

NCT01829971
View directory record Official record
Conditions
Primary Liver Cancer, SCLC, Lymphoma, Melanoma, Multiple Myeloma, Renal Cell Carcinoma, NSCLC
Interventions
MRX34
Drug
Lead sponsor
Mirna Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
6
States / cities
Scottsdale, Arizona • Dallas, Texas • Houston, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 27, 2016 · Synced Oct 9, 2026, 5:08 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

A Study of Dapansutrile Plus Pembrolizumab in Patients With PD-1 Refractory Advanced Melanoma

NCT04971499
View directory record Official record
Conditions
Melanoma
Interventions
Dapansutrile, Pembrolizumab
Drug
Lead sponsor
April Salama, M.D.
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 20, 2026 · Synced Oct 9, 2026, 5:08 AM EDT
Recruiting Phase 2 Interventional

A Clinical Study of Intismeran Autogene (V940) and Pembrolizumab (MK-3475) in People With Melanoma (V940-012/INTerpath-012)

NCT06961006
View directory record Official record
Conditions
Malignant Melanoma
Interventions
Intismeran autogene, Pembrolizumab, Placebo
Biological · Other
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
5
States / cities
Springdale, Arkansas • San Francisco, California • Hackensack, New Jersey + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 9, 2026, 5:08 AM EDT
Completed Phase 2 Interventional Results available

Stereotactic Radiation Therapy and Ipilimumab in Treating Patients With Metastatic Melanoma

NCT02107755
View directory record Official record
Conditions
Liver Metastases, Lung Metastases, Recurrent Melanoma, Stage IV Melanoma, Tumors Metastatic to Brain
Interventions
ipilimumab, stereotactic radiosurgery, laboratory biomarker analysis
Biological · Radiation · Other
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated May 21, 2024 · Synced Oct 9, 2026, 5:08 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

A Study to Assess IPN01194 When Administered Alone in Adults With Advanced Solid Tumours

NCT06305247
View directory record Official record
Conditions
Melanoma, Head and Neck Squamous Cell Carcinoma, Pancreatic Ductal Adenocarcinoma, Colorectal Cancer, Solid Tumor
Interventions
IPN01194
Drug
Lead sponsor
Ipsen
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
5
States / cities
Los Angeles, California • San Diego, California • New Haven, Connecticut + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 9, 2026, 5:08 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Pembrolizumab and All-Trans Retinoic Acid Combination Treatment of Advanced Melanoma

NCT03200847
View directory record Official record
Conditions
Stage IV Melanoma, Stage III Melanoma, Advanced Melanoma
Interventions
Pembrolizumab with All-Trans Retinoic Acid
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 100 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
2
States / cities
Aurora, Colorado • Fort Collins, Colorado
Source: ClinicalTrials.gov public record
Updated Oct 1, 2024 · Synced Oct 9, 2026, 5:08 AM EDT
Recruiting Early Phase 1 Interventional

Feasibility Study on the Effect of a Methionine-Reduced Diet on Serum Levels in Pts w/ Solid Tumors

NCT07628634
View directory record Official record
Conditions
Adenocarcinoma, Basal Cell Carcinoma, Squamous Cell Carcinoma, Transitional Cell Carcinoma, Ductal Carcinoma, Osteosarcoma, Soft Tissue Sarcoma, Ewing Sarcoma, Rhabdomyosarcoma, Leiomyosarcoma, Melanoma, Germ Cell Tumor, Lymphoma, Endocrine Tumor, Glioma
Interventions
Methionine-Reduced Diet
Other
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Jul 31, 2026 · Synced Oct 9, 2026, 5:08 AM EDT
Completed Phase 1 Interventional

Intratumoral CAVATAK (CVA21) and Pembrolizumab in Patients With Advanced Melanoma (VLA-011 CAPRA)

NCT02565992
View directory record Official record
Conditions
Melanoma
Interventions
CAVATAK, Pembrolizumab
Biological · Drug
Lead sponsor
Viralytics
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
3
States / cities
Santa Monica, California • New Brunswick, New Jersey • Canton, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 17, 2023 · Synced Oct 9, 2026, 5:08 AM EDT
Completed Phase 2 Interventional

BMS-247550 in Treating Patients With Stage IV Melanoma

NCT00036764
View directory record Official record
Conditions
Recurrent Melanoma, Stage IV Melanoma
Interventions
ixabepilone, pharmacogenomic studies, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 25, 2013 · Synced Oct 9, 2026, 5:08 AM EDT
Terminated Phase 1 Interventional

NM32-2668 in Adult Patients With Selected Advanced Solid Tumors

NCT06299163
View directory record Official record
Conditions
Ovarian Carcinoma, Fallopian Tube Carcinoma, Peritoneal Carcinoma, Endometrial Cancer, Adenocarcinoma of Lung, Triple Negative Breast Cancer, Liposarcoma, Leiomyosarcoma, Mesothelioma, Malignant, Adenocarcinoma - Gastroesophageal Junction (GEJ), Adenocarcinoma of the Stomach, Melanoma, Malignant, Renal Cell Carcinoma
Interventions
NM32-2668
Biological
Lead sponsor
Numab Therapeutics AG
Industry
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
11
States / cities
Birmingham, Alabama • Los Angeles, California • Chicago, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2025 · Synced Oct 9, 2026, 5:08 AM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Collection of Tissue & Blood From Patients w/ Benign & Malignant Tumors of the Soft Tissue & Gastrointestinal Tract

NCT00582647
View directory record Official record
Conditions
Esophageal Cancer, Bile Duct Neoplasms, Gastric Cancer, Liver Cancer, Melanoma, Pancreatic Cancer, Sarcoma
Interventions
Not listed
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
6,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2000 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 15, 2026 · Synced Oct 9, 2026, 5:08 AM EDT
Completed Phase 1 Interventional

Sodium Stibogluconate and IFNa-2b Followed By CDDP, VLB and DTIC Treating Pts.With Advanced Melanoma or Other Cancers

NCT00498979
View directory record Official record
Conditions
Stage IV Melanoma
Interventions
recombinant interferon alfa-2b, cisplatin, sodium stibogluconate, dacarbazine, vinblastine
Biological · Drug
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 24, 2020 · Synced Oct 9, 2026, 5:08 AM EDT
Completed Phase 1 Interventional

An Expanded Cohort Trial of Bortezomib and Sorafenib in Advanced Malignant Melanoma

NCT01078961
View directory record Official record
Conditions
Melanoma
Interventions
bortezomib, sorafenib
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 8, 2016 · Synced Oct 9, 2026, 5:08 AM EDT
Terminated No phase listed Observational

YASU Research Registry: For Young Adults With Cancer

NCT06275854
View directory record Official record
Conditions
Cancer, Leukemia, Sarcoma, Germ Cell Cancer, Lymphoma, Colorectal Cancer, Melanoma, Breast Cancer
Interventions
Not listed
Lead sponsor
Young Adult Survivors United
Other
Eligibility
18 Years and older
Enrollment
192 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Wexford, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 14, 2025 · Synced Oct 9, 2026, 5:08 AM EDT
Terminated Phase 2 Interventional Results available

Niraparib in the Treatment of Patients With Advanced PALB2 Mutated Tumors

NCT05169437
View directory record Official record
Conditions
Solid Tumor, Breast Tumor, Colon Tumor, Malignant, Lung Tumor, Urologic Cancer, Pancreatic Cancer, Melanoma, Metastatic Cancer, Locally Advanced Solid Tumor, Esophageal Cancer, Endometrial Cancer, Head and Neck Cancer
Interventions
Niraparib
Drug
Lead sponsor
Tempus AI
Industry
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
80
States / cities
Yuma, Arizona • Springdale, Arkansas • Fountain Valley, California + 69 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2025 · Synced Oct 9, 2026, 5:08 AM EDT
Active, not recruiting Phase 2 Interventional

Infliximab for Treatment of Immune Checkpoint Inhibitor Colitis

NCT04305145
View directory record Official record
Conditions
Melanoma Stage III, Melanoma Stage IV, Skin Cancer Stage III, Skin Cancer Stage IV, Drug-Induced Colitis, Drug Toxicity, Immune-related Adverse Event
Interventions
Infliximab, Methylprednisolone, Prednisone
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2030
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Oct 9, 2026, 5:08 AM EDT
Completed No phase listed Observational

Cost of Adverse Events Related to How Often Follow-Up Occurs Among Patients With Cancer That Has Spread

NCT03165409
View directory record Official record
Conditions
Melanoma
Interventions
Nivolumab, Ipilimumab
Biological
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
1,828 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
Princeton, New Jersey
Source: ClinicalTrials.gov public record
Updated Oct 5, 2017 · Synced Oct 9, 2026, 5:08 AM EDT
Terminated Not applicable Interventional

7T MRI Scan for the Early Detection of Melanoma Brain Metastases

NCT04941430
View directory record Official record
Conditions
Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Malignant Neoplasm in the Brain, Metastatic Melanoma, Pathologic Stage IV Cutaneous Melanoma AJCC v8
Interventions
Magnetic Resonance Imaging using 7 Tesla MRI
Diagnostic Test
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 12, 2025 · Synced Oct 9, 2026, 5:08 AM EDT
Not listed Phase 2 Interventional

Sunitinib, Tamoxifen, and Cisplatin in Treating Patients With High-Risk Ocular Melanoma

NCT00489944
View directory record Official record
Conditions
Intraocular Melanoma
Interventions
cisplatin, sunitinib malate, tamoxifen citrate, adjuvant therapy
Drug · Procedure
Lead sponsor
San Diego Pacific Oncology & Hematology Associates
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
1
States / cities
Encinitas, California
Source: ClinicalTrials.gov public record
Updated Jan 10, 2014 · Synced Oct 9, 2026, 5:08 AM EDT
Completed No phase listed Observational

Sun Exposure and Melanoma in Agricultural Workers

NCT00901966
View directory record Official record
Conditions
Melanoma
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 100 Years
Enrollment
447 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 28, 2020 · Synced Oct 9, 2026, 5:08 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

The Incidence of Breast and Other Cancers Among Female Flight Attendants

NCT00342407
View directory record Official record
Conditions
Thyroid Cancer, Breast Cancer, Non-Melanoma Skin Cancer, Melanoma
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 100 Years · Female only
Enrollment
6,093 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2001 – 2020
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 10, 2020 · Synced Oct 9, 2026, 5:08 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Sunscreen Based on Bioadhesive Nanoparticles

NCT02668536
View directory record Official record
Conditions
Melanoma, UV Ray Skin Damage
Interventions
Standard Sunscreen, BNP
Drug · Device
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 13, 2018 · Synced Oct 9, 2026, 5:08 AM EDT